Komori
Mitsubishi Chemical Group (4188) · InitiativeAchieved

Transfer of 田辺三菱製薬 to the best owner

First written in FY2025. 1 of 2 entries say "Achieved", first in FY2026-H1. Latest entry: FY2026-H1.

2entries
1years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY20252025: 22025
Same theme, other companies
Transfer of Mitsubishi Tanabe Pharma Corporation under Bain CapitalA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026-H1AchievedAnnual report

    「In June 2025, the Company's annual general meeting of shareholders approved the absorption-type company split agreement to transfer all shares of its subsidiary 田辺三菱製薬 and related assets to BCJ-94 Co., Ltd., a special-purpose company indirectly owned by an investment fund advised by Bain Capital Private Equity, LP. The transaction was completed on 1 July 2025.」

    The transfer of 田辺三菱製薬 to the best owner for its future regrowth was completed through an absorption-type company split on 1 July 2025, following shareholder approval. As a result, the company and its subsidiaries and other entities changed from subsidiaries of the Company to entities outside the Group and were classified as discontinued operations.
  2. FY2025First statedAnnual report

    「In February 2025, the Company resolved that 田辺三菱製薬株式会社 would be transferred to 株式会社BCJ-94, a special-purpose company headquartered in Chiyoda-ku, Tokyo, whose shares are indirectly held by an investment fund advised by Bain Capital Private Equity, LP, headquartered in the United States. The decision was based on a comprehensive assessment, including the alignment of management policies for the future regrowth of 田辺三菱製薬株式会社. Subject to approval at the ordinary general meeting of shareholders and completion of the necessary clearances and approvals under competition laws and other applicable laws and regulations in Japan and overseas, the transfer is expected to be completed in the second quarter of the fiscal year ending March 2026.」

    For the future regrowth of the pharma business, the Company resolved to transfer 田辺三菱製薬 to BCJ-94, which is held by an investment fund of Bain Capital. In March 2025, it entered into an absorption-type company split agreement and announced consideration of approximately ¥510.0 billion, with the transaction scheduled to become effective on 1 July 2025.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Mitsubishi Chemical Group yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.